Univest
Univest
  • Markets

Aarti Pharmalabs (AARTIPHARM) 52 Week High Streak: Stock Hits Fresh High for Second Straight Session

  • November 17, 2026
  • Posted by: Kunal Singla
  • Category: News
No Comments
Aarti Pharmalabs 52 Week High Streak
Aarti Pharmalabs Ltd. (AARTIPHARM) share price reached a fresh 52-week high of Rs 1,033.6 today and later stood at Rs 1,032.95, up 4.74% from the previous close. Market cap was Rs 9,062.09 crore.

Aarti Pharmalabs 52 Week High Streak: Aarti Pharmalabs Ltd. (AARTIPHARM) has now set a fresh 52-week high for its second straight session, taking the cumulative move across the run to 3.36% since 16 November 2026. The stock touched a peak of Rs 1,033.60 and was trading at Rs 1,032.95 as of 17 November 2026 at 10:07 AM IST. According to Univest data, the price pattern is confirmed, but no company-specific catalyst is established for the continued move.

Against the previous close of Rs 986.25, the stock is up Rs 46.70, or 4.74%, after opening at Rs 999.00 and touching a low of Rs 980.20. Market capitalisation stands at Rs 9,062.09 crore. Unlike a single-day breakout, the Aarti Pharmalabs 52 Week High Streak shows a repeated one-year high on back-to-back sessions, which makes the cumulative move and the valuation after it the more useful reference points.

Table of Contents

Toggle
  • Aarti Pharmalabs 52 Week High Streak: Consecutive High Analysis
  • Aarti Pharmalabs Ltd. (AARTIPHARM) 52 Week High Streak: Consecutive High Analysis
  • What the Repeated 52-Week Highs Show
  • Aarti Pharmalabs Ltd. (AARTIPHARM) Fundamental Analysis
  • Sector and Industry Context
  • Peer Comparison
  • Why Investors Are Watching Aarti Pharmalabs
  • About Aarti Pharmalabs
  • Track Aarti Pharmalabs on Univest
  • Frequently Asked Questions
    • How many sessions has Aarti Pharmalabs set a 52-week high?
    • What is the Aarti Pharmalabs 52 Week High Streak gain?
    • Why is Aarti Pharmalabs hitting new 52-week highs?
    • What is the Aarti Pharmalabs share price today?
    • What is the Aarti Pharmalabs market cap?
    • What are the P/E and P/B ratios of Aarti Pharmalabs?
    • How does Aarti Pharmalabs compare with the Pharmaceuticals & Drugs industry?
    • How does Aarti Pharmalabs compare with its peers?
  • Track Aarti Pharmalabs Ltd. (AARTIPHARM) Share Price on Univest

Aarti Pharmalabs 52 Week High Streak: Consecutive High Analysis

The Aarti Pharmalabs 52 Week High Streak is now two sessions old. Univest data shows a fresh 52-week high on 16 November 2026 and again on 17 November 2026, with the current 52-week high at Rs 1,033.60. That level equals today’s day high, so the latest peak was set during the current session.

Across the run, Aarti Pharmalabs has moved 3.36% cumulatively. Today’s contribution is Rs 46.70, or 4.74%, from a previous close of Rs 986.25 to the latest traded price of Rs 1,032.95. The day opened at Rs 999.00, touched a low of Rs 980.20 and then reached Rs 1,033.60, so the latest traded price sits at the very top of the day’s range.

Market capitalisation is Rs 9,062.09 crore as of 10:07 AM IST. This Aarti Pharmalabs 52 Week High Streak reading is about price only. Univest data confirms the repeated highs but does not establish a company-specific catalyst, so the move is best read as a price event and not as a response to a confirmed development. Because the session is still open, the latest traded price and the day’s high can change as trading continues.

Aarti Pharmalabs Ltd. (AARTIPHARM) 52 Week High Streak: Consecutive High Analysis

Metric Value
Current Price Rs 1,032.95
Previous Close Rs 986.25
Today's Move +Rs 46.7 (+4.74%)
Open Rs 999
High Rs 1,033.6
Low Rs 980.2
Market Capitalisation Rs 9,062.09 crore

Aarti Pharmalabs Ltd. (AARTIPHARM) traded at Rs 1,032.95 versus the previous close of Rs 986.25, a rise of 4.74%. The stock opened at Rs 999, reached a high of Rs 1,033.6 and touched a low of Rs 980.2.

What the Repeated 52-Week Highs Show

Repeated 52-week highs show that the stock has kept moving above its own one-year peak on consecutive sessions. They confirm a price pattern, not a reason. In the Aarti Pharmalabs 52 Week High Streak, the cumulative move of 3.36% is the figure that a single-session reading cannot show.

The pattern carries two readings, and both stay within what the data states. First, the stock has moved above its yearly peak twice in a row, which is what the “second straight session” label records. Second, today’s change of 4.74% is larger than the cumulative 3.36%, so the full Aarti Pharmalabs 52 Week High Streak is a smaller figure than the move on the latest day alone.

A repeated high does not say how long the run will last, and it does not say that the next session will extend it. It also does not say that the move rests on a business development, since Univest data does not establish a catalyst. Readers tracking the Aarti Pharmalabs 52 Week High Streak can compare the current price of Rs 1,032.95 with the 52-week high of Rs 1,033.60 as the session progresses, and watch whether the stock records a third straight session at a fresh one-year high.

Aarti Pharmalabs Ltd. (AARTIPHARM) Fundamental Analysis

Metric Value
Market Capitalisation Rs 9,062.09 crore
P/E Ratio 34.84x
P/B Ratio 3.97x
ROE 8.5%
ROCE 10.77%
EPS Rs 28.31
Book Value Per Share Rs 248.65
Dividend Yield 0.35%

Aarti Pharmalabs Ltd. (AARTIPHARM) fundamental metrics show P/E 34.84x, P/B 3.97x, ROE 8.5%, ROCE 10.77%. Taken on their own, these numbers offer context rather than a trading signal.

Aarti Pharmalabs Ltd. has a market capitalisation of Rs 9,062.09 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 34.84x, P/B at 3.97x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 8.5% and ROCE of 10.77%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 28.31, book value per share of Rs 248.65, dividend yield of 0.35%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 30.35x, median ROE of 11.43%, median ROCE of 13.1%. They set out the fundamental picture and are not a rating on the stock.

Sector and Industry Context

Metric Value
Sector Healthcare
Industry Pharmaceuticals & Drugs
Benchmark Scope same industry
Company P/E Ratio 34.84x
Benchmark Median P/E 30.35x
Benchmark Average P/E 52.2x
Benchmark P/E Range 2.82x to 1,227.27x
Company P/B Ratio 3.97x
Benchmark Median P/B 2.9x
Company ROE 8.5%
Benchmark Median ROE 11.43%
Company ROCE 10.77%
Benchmark Median ROCE 13.1%
Company Market Capitalisation Rs 9,062.09 crore
Benchmark Median Market Cap Rs 756.71 crore

Aarti Pharmalabs Ltd. (AARTIPHARM) operates in the Healthcare sector, within the Pharmaceuticals & Drugs industry.

Aarti Pharmalabs Ltd. (AARTIPHARM) has a P/E ratio of 34.84x, which is above the benchmark median of 30.35x, a difference of +14.79%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Aarti Pharmalabs Ltd. (AARTIPHARM) has a ROE of 8.5%, which is below the benchmark median of 11.43%, a difference of -25.63%. Aarti Pharmalabs Ltd. (AARTIPHARM) has a ROCE of 10.77%, which is below the benchmark median of 13.1%, a difference of -17.79%.

Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.

Peer Comparison

Company Symbol Market Cap (Cr) P/E P/B ROE (%) ROCE (%)
Procter & Gamble Health Ltd. PGHL 9,295.4 24.47 14.13 62.18 84.86
Strides Pharma Science Ltd. STAR 9,350.76 14.74 2.66 20.31 18.57
Sanofi Consumer Healthcare India Ltd. SANOFICONR 8,329.02 29.78 19.62 73.2 98.11
Blue Jet Healthcare Ltd. BLUEJET 10,201.96 34.04 4.23 19.88 27.18
SYMBIOTEC PHARMALAB LTD SYMBIOTEC 10,371.26 91.71 7.41 11.22 12.41

Aarti Pharmalabs Ltd. (AARTIPHARM) has a P/E ratio of 34.84x compared with the displayed peer median of 29.78x. The comparison is relative and should not be read as a recommendation. Its ROE of 8.5% compares with a peer median of 20.31% across the companies shown in the table. ROCE stood at 10.77% versus the displayed peer median of 27.18%, providing a capital-efficiency comparison. Aarti Pharmalabs Ltd. (AARTIPHARM) has a market capitalisation of Rs 9,062.09 crore. Among the 5 peers shown, 4 have a larger market capitalisation.

Why Investors Are Watching Aarti Pharmalabs

  • Aarti Pharmalabs has set a fresh 52-week high for its second straight session.
  • The cumulative move across the streak is 3.36%.
  • The latest traded price of Rs 1,032.95 is close to the 52-week high of Rs 1,033.60.
  • The P/E of 34.84 is 14.79% above the same-industry median of 30.35.
  • ROE of 8.50% and ROCE of 10.77% are below their industry medians of 11.43% and 13.1%.

About Aarti Pharmalabs

Aarti Pharmalabs Ltd. (AARTIPHARM) is a listed company in the Healthcare sector, classified under Pharmaceuticals & Drugs. Its market capitalisation is Rs 9,062.09 crore. For readers following the Aarti Pharmalabs 52 Week High Streak, the relevant context is the industry it is benchmarked against: pharmaceutical companies are commonly read through P/E, P/B and return ratios, which is why the P/E of 34.84, the P/B of 3.97, the ROE of 8.50% and the ROCE of 10.77% sit alongside the price move in this article. The company’s position against 198 same-industry companies is covered in the sector section above.

Track Aarti Pharmalabs on Univest

Univest carries the latest share price, 52-week high, valuation ratios and peer figures for Aarti Pharmalabs Ltd. Readers following the Aarti Pharmalabs 52 Week High Streak can check the stock page as the session progresses to see whether the stock records a further fresh 52-week high, and compare the updated price with the figures in this article.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Reg. No. INH000013776, a subsidiary of Univest Communication Technologies Private Limited).

Frequently Asked Questions

How many sessions has Aarti Pharmalabs set a 52-week high?

Ans. Aarti Pharmalabs has set a fresh 52-week high for its second straight session, on 16 November 2026 and again on 17 November 2026. The current 52-week high is Rs 1,033.60, and the Aarti Pharmalabs 52 Week High Streak is two sessions old as of 10:07.

What is the Aarti Pharmalabs 52 Week High Streak gain?

Ans. The cumulative move across the Aarti Pharmalabs 52 Week High Streak is 3.36%. Today's change is Rs 46.70, or 4.74%, from a previous close of Rs 986.25 to the latest traded price of Rs 1,032.95, as of 17 November 2026 at 10:07 AM IST.

Why is Aarti Pharmalabs hitting new 52-week highs?

Ans. According to Univest data, the repeated one-year highs are confirmed as a price pattern, but no company-specific catalyst is established. The Aarti Pharmalabs 52 Week High Streak should therefore be read as a price event and not as a response to a confirmed development.

What is the Aarti Pharmalabs share price today?

Ans. Aarti Pharmalabs was trading at Rs 1,032.95 as of 17 November 2026 at 10:07 AM IST, up 4.74% from the previous close of Rs 986.25. The day's range so far is Rs 980.20 to Rs 1,033.60.

What is the Aarti Pharmalabs market cap?

Ans. Aarti Pharmalabs has a market capitalisation of Rs 9,062.09 crore as of 17 November 2026. Market capitalisation indicates company size and not quality, so the Aarti Pharmalabs 52 Week High Streak should be read alongside P/E, P/B, ROE and ROCE.

What are the P/E and P/B ratios of Aarti Pharmalabs?

Ans. Aarti Pharmalabs has a P/E ratio of 34.84 and a P/B ratio of 3.97. EPS is Rs 28.31 and book value is Rs 248.65, unchanged across the streak, so the change in both multiples comes from the share price.

How does Aarti Pharmalabs compare with the Pharmaceuticals & Drugs industry?

Ans. Its P/E of 34.84 is 14.79% above the same-industry median of 30.35, and its P/B of 3.97 is 36.9% above the median of 2.9. ROE of 8.50% is 25.63% below the industry median of 11.43%.

How does Aarti Pharmalabs compare with its peers?

Ans. Among the five peers shown, P/E ranges from 14.74 to 91.71, so Aarti Pharmalabs's 34.84 is above four of them. Its ROE of 8.50% and ROCE of 10.77% are below all five peers, and its P/B of 3.97 is above one peer.

Track Aarti Pharmalabs Ltd. (AARTIPHARM) Share Price on Univest

Use Aarti Pharmalabs Ltd. (AARTIPHARM) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.



Author: Kunal Singla
Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.

Leave a Reply Cancel reply